Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Viridian Seeds is a private ag-biotech company developing improved legume crops, or "super-legumes," for sustainable agriculture and plant-based food systems. The company applies genomics, computational biology, AI-assisted allele discovery, TILLING-based mutation screening, and CRISPR gene editing to create non-GMO and gene-edited protein crops with higher yield, improved nutrition, and better biotic and abiotic stress tolerance. Its crop focus includes yellow peas, lentils, chickpeas, kidney beans, and lupins. Viridian Seeds appears to operate at an R&D and early commercialization stage rather than as a human therapeutics company, with its value proposition centered on climate-smart crop improvement and sustainable plant protein production.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Viridian Seeds.